• Five sites recruiting in US study of DLL3-targeting 212Pb-labelled Radio-DARPin MP0712
  • Dosing ongoing in first patients, consecutively moving to subsequent dosing cycles
  • Initial data anticipated within the coming months, comprehensive efficacy data expected in 2027